Hu Xiao-Yan, Bai Hai, Pan Yao-Zhu, Wnag Cun-Bang, Wu Bing, Zhao Qiang, Ai Hao, Chen Zhe, Han Xia
Department of Hematology, Lanzhou General Hospital, Lanzhou Military Area, Lanzhou 730050, Gansu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Jun;19(3):598-601.
This study was purposed to detect the expression of autophagy-related gene Beclin1 and microtubule-associated protein 1 light chain 3 (MAPLC3) in bone marrow mononuclear cells (BMMNC) isolated from acute leukemia (AL) patients, and to explore its significance. Transmission electron microscopy and RT-PCR were used to detect the autophagy activity and the expression level of Beclin1 and MAPLC3 mRNA in BMMNC isolated from 27 AL patients with de novo, refractory or relapse AL and completely remission and 31 normal persons respectively. The results showed that autophagy activity and expression levels of Beclin1 and MAPLC3 mRNA in BMMNC from de novo AL patients were 80%, 0.68 ± 0.18, 0.24 ± 0.06, respectively; those in BMMNC from refractory or relapse AL patients were 100%, 0.79 ± 0.09, 0.30 ± 0.07, respectively; those in BMMNC from CR patients were 40%, 0.52 ± 0.15, 0.16 ± 0.04, respectively, while those in BMMNC from normal persons were 20%, 0.57 ± 0.13, 0.16 ± 0.05, respectively. The autophagic activity and expression levels of Beclin1 and MAPLC3 mRNA in de novo and refractory or relapse AL patients were higher than those in normal persons, with statistical significance (p < 0.05), while the comparison between CR patients and normal control showed no statistical difference (p > 0.05). It is concluded that autophagy activity and Beclin1 and MAPLC3 mRNA expression level of in de novo and refractory or relapse patients are higher than those in normal control, and the up-regulation of autophagy activity and expression of Beclin1 and MAPLC3 mRNA in refractory or relapse patients is especially significant. This may be related to the genesis, development and drug resistance of AL.
本研究旨在检测急性白血病(AL)患者分离的骨髓单个核细胞(BMMNC)中自噬相关基因Beclin1和微管相关蛋白1轻链3(MAPLC3)的表达,并探讨其意义。分别采用透射电子显微镜和RT-PCR检测27例初发、难治或复发AL及完全缓解的AL患者以及31例正常人分离的BMMNC中的自噬活性及Beclin1和MAPLC3 mRNA的表达水平。结果显示,初发AL患者BMMNC中的自噬活性及Beclin1和MAPLC3 mRNA表达水平分别为80%、0.68±0.18、0.24±0.06;难治或复发AL患者BMMNC中的分别为100%、0.79±0.09、0.30±0.07;完全缓解(CR)患者BMMNC中的分别为40%、0.52±0.15、0.16±0.04,而正常人BMMNC中的分别为20%、0.57±0.13、0.16±0.05。初发及难治或复发AL患者的自噬活性及Beclin1和MAPLC3 mRNA表达水平高于正常人,差异有统计学意义(p<0.05),而CR患者与正常对照比较差异无统计学意义(p>0.05)。结论:初发及难治或复发患者的自噬活性及Beclin1和MAPLC3 mRNA表达水平高于正常对照,难治或复发患者自噬活性及Beclin1和MAPLC3 mRNA表达上调尤为明显。这可能与AL的发生、发展及耐药有关。